c-JUN promotes BCR-ABL-induced lymphoid leukemia by inhibiting methylation of the 5' region of CDK6

Blood

Volumn 117, Issue 15, 2011, Pages 4065-4075

  Kollmann, Karoline ^a,b   Heller, Gerwin ^a   Ott, Rene Georg ^a   Scheicher, Ruth ^a   Zebedin Brandl, Eva ^a   Schneckenleithner, Christine ^a,b   Simma, Olivia ^a   Warsch, Wolfgang ^a   Eckelhart, Eva ^a   Hoelbl, Andrea ^a   Bilban, Martin ^a   Zochbauer Muller, Sabine ^a   Malumbres, Marcos ^c   Sexl, Veronika ^a,b  

^a MEDICAL UNIVERSITY OF VIENNA   (Austria)

^b UNIVERSITY OF VETERINARY MEDICINE   (Austria)

^c Centro Nacional de Investigaciones Oncológicas   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; CYCLIN DEPENDENT KINASE 6; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; PROTEIN C JUN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CELL VIABILITY; CPG ISLAND; DNA METHYLATION; DOWN REGULATION; ENZYME BLOOD LEVEL; LEUKEMOGENESIS; LYMPHATIC LEUKEMIA; MOUSE; NEWBORN; NONHUMAN; PHENOTYPE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

EID: 79954616085     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2010-07-299644     Document Type: Article

References (50)

1. Shaulian E, Karin M. AP-1 as a regulator of cell life and death. Nat Cell Biol. 2002;4(5):E131-E136. (Pubitemid 34521026)
2. Hess J, Angel P, Schorpp-Kistner M. AP-1 subunits: quarrel and harmony among siblings. J Cell Sci. 2004;117(pt 25):5965-5973. (Pubitemid 40123963)
3. Wagner EF, Eferl R. Fos/AP-1 proteins in bone and the immune system. Immunol Rev. 2005;208:126-140. (Pubitemid 41746389)
4. Hai T, Curran T. Cross-family dimerization of transcription factors Fos/Jun. and ATF/CREB alters DNA binding specificity. Proc Natl Acad Sci U S A. 1991;88(9):3720-3724. (Pubitemid 21916695)
5. Chinenov Y, Kerppola TK. Close encounters of many kinds: Fos-Jun. interactions that mediate transcription regulatory specificity. Oncogene. 2001;20(19):2438-2452. (Pubitemid 32531301)
6. Hilberg F, Aguzzi A, Howells N, Wagner EF. c-jun is essential for normal mouse development and hepatogenesis. Nature. 1993;365(6442):179-181. (Pubitemid 23282066)
7. Eferl R, Sibilia M, Hilberg F, et al. Functions of c-Jun. in liver and heart development. J Cell Biol. 1999;145(5):1049-1061. (Pubitemid 29270062)
8. Jochum W, Passegue E, Wagner EF. AP-1 in mouse development and tumorigenesis. Oncogene. 2001;20(19):2401-2412. (Pubitemid 32531298)
9. Zhang W, Hart J, McLeod HL, Wang HL. Differential expression of the AP-1 transcription factor family members in human colorectal epithelial and neuroendocrine neoplasms. Am J Clin Pathol. 2005;124(1):11-19. (Pubitemid 40944368)
10. Vleugel MM, Greijer AE, Bos R, van der Wall E, van Diest PJ. c-Jun. activation is associated with proliferation and angiogenesis in invasive breast cancer. Hum Pathol. 2006;37(6):668-674. (Pubitemid 43956532)
11. Lopez-Bergami P, Huang C, Goydos JS, et al. Rewired ERK-JNK signaling pathways in melanoma. Cancer Cell. 2007;11(5):447-460. (Pubitemid 46670078)
12. Mariani O, Brennetot C, Coindre JM, et al. JUN oncogene amplification and overexpression block adipocytic differentiation in highly aggressive sarcomas. Cancer Cell. 2007;11(4):361-374. (Pubitemid 46518313)
13. Szremska AP, Kenner L, Weisz E, et al. JunB inhibits proliferation and transformation in B-lymphoid cells. Blood. 2003;102(12):4159-4165. (Pubitemid 37487003)
14. Young MR, Li JJ, Rincon M, et al. Transgenic mice demonstrate AP-1 (activator protein-1) transactivation is required for tumor promotion. Proc Natl Acad Sci U S A. 1999;96(17):9827-9832. (Pubitemid 29398817)
15. Eferl R, Wagner EF. AP-1: a double-edged sword in tumorigenesis. Nat Rev Cancer. 2003;3(11):859-868. (Pubitemid 37383716)
16. Bakiri L, Lallemand D, Bossy-Wetzel E, Yaniv M. Cell cycle-dependent variations in c-Jun. and JunB phosphorylation: a role in the control of cyclin D1 expression. EMBO J. 2000;19(9):2056-2068. (Pubitemid 30237581)
17. Eferl R, Ricci R, Kenner L, et al. Liver tumor development. c-Jun. antagonizes the proapoptotic activity of p53. Cell. 2003;112(2):181-192. (Pubitemid 36144108)
18. Kasibhatla S, Brunner T, Genestier L, Echeverri F, Mahboubi A, Green DR. DNA damaging agents induce expression of Fas ligand and subsequent apoptosis in T lymphocytes via the activation of NF-kappa B and AP-1. Mol Cell. 1998;1(4):543-551. (Pubitemid 128374690)
19. Raitano AB, Halpern JR, Hambuch TM, Sawyers CL. The Bcr-Abl leukemia oncogene activates Jun. kinase and requires Jun. for transformation. Proc Natl Acad Sci U S A. 1995;92(25):11746-11750. (Pubitemid 26014190)
20. Burgess GS, Williamson EA, Cripe LD, et al. Regulation of the c-jun gene in p210 BCR-ABL-transformed cells corresponds with activity of JNK, the c-jun N-terminal kinase. Blood. 1998;92(7):2450-2460. (Pubitemid 28452988)
21. Hess P, Pihan G, Sawyers CL, Flavell RA, Davis RJ. Survival signaling mediated by c-Jun. NH (2)-terminal kinase in transformed B lymphoblasts. Nat Genet. 2002;32(1):201-205. (Pubitemid 34977219)
22. Gururajan M, Chui R, Karuppannan AK, Ke J, Jennings CD, Bondada S. c-Jun. N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood. 2005;106(4):1382-1391. (Pubitemid 41129605)
23. Knoepfler PS, Zhang XY, Cheng PF, Gafken PR, McMahon SB, Eisenman RN. Myc influences global chromatin structure. EMBO J. 2006;25(12):2723-2734. (Pubitemid 43980380)
24. Esteller M. Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet. 2007;8(4):286-298. (Pubitemid 46439286)
25. Jones PA, Baylin SB. The epigenomics of cancer. Cell. 2007;128(4):683-692. (Pubitemid 46273572)
26. Suzuki MM, Bird A. DNA methylation landscapes: provocative insights from epigenomics. Nat Rev Genet. 2008;9(6):465-476. (Pubitemid 351693975)
27. Behrens A, Sibilia M, David JP, et al. Impaired postnatal hepatocyte proliferation and liver regeneration in mice lacking c-jun in the liver. EMBO J. 2002;21(7):1782-1790. (Pubitemid 34614634)
28. Rickert RC, Roes J, Rajewsky K. B lymphocytespecific, Cre-mediated mutagenesis in mice. Nucleic Acids Res. 1997;25(6):1317-1318.
29. Sabapathy K, Kallunki T, David JP, Graef I, Karin M, Wagner EF. c-Jun. NH2-terminal kinase (JNK) 1 and JNK2 have similar and stagedependent roles in regulating T cell apoptosis and proliferation. J Exp Med. 2001;193(3):317-328. (Pubitemid 32524515)
30. Behrens A, Sibilia M, Wagner EF. Amino-terminal phosphorylation of c-Jun. regulates stressinduced apoptosis and cellular proliferation. Nat Genet. 1999;21(3):326-329. (Pubitemid 29124945)
31. Donehower LA, Harvey M, Slagle BL, et al. Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours. Nature. 1992;356(6366):215-221.
32. Malumbres M, Sotillo R, Santamaria D, et al. Mammalian cells cycle without the D-type cyclindependent kinases Cdk4 and Cdk6. Cell. 2004;118(4):493-504. (Pubitemid 39485668)
33. Shinkai Y, Rathbun G, Lam KP, et al. RAG-2-deficient mice lack mature lymphocytes owing to inability to initiate V (D) J rearrangement. Cell. 1992;68(5):855-867.
34. Sexl V, Piekorz R, Moriggl R, et al. Stat5a/b contribute to interleukin 7-induced B-cell precursor expansion, but abl-and bcr/abl-induced transformation are independent of stat5. Blood. 2000;96(6):2277-2283.
35. Ott RG, Simma O, Kollmann K, et al. JunB is a gatekeeper for B-lymphoid leukemia. Oncogene. 2007;26(33):4863-4871. (Pubitemid 47093176)
36. Kerenyi MA, Grebien F, Gehart H, et al. Stat5 regulates cellular iron uptake of erythroid cells via IRP-2 and TfR-1. Blood. 2008;112(9):3878-3888.
37. Li LC, Dahiya R. MethPrimer: designing primers for methylation PCRs. Bioinformatics. 2002;18(11):1427-1431. (Pubitemid 35414532)
38. Unnikrishnan I, Radfar A, Jenab-Wolcott J, Rosenberg N. p53 mediates apoptotic crisis in primary Abelson virus-transformed pre-B cells. Mol Cell Biol. 1999;19(7):4825-4831. (Pubitemid 29289521)
39. Hoelbl A, Schuster C, Kovacic B, et al. Stat5 is indispensable for the maintenance of bcr/ablpositive leukaemia. EMBO Mol Med. 2010;2(3):98-110.
40. Okano M, Xie S, Li E. Cloning and characterization of a family of novel mammalian DNA (cytosine-5) methyltransferases. Nat Genet. 1998;19(3):219-220. (Pubitemid 28309328)
41. Okano M, Bell DW, Haber DA, Li E. DNA methyltransferases Dnmt3a and Dnmt3b are essential for de novo methylation and mammalian development. Cell. 1999;99(3):247-257. (Pubitemid 29519904)
42. Robertson KD, Uzvolgyi E, Liang G, et al. The human DNA methyltransferases (DNMTs) 1, 3a and 3b: coordinate mRNA expression in normal tissues and overexpression in tumors. Nucleic Acids Res. 1999;27(11):2291-2298. (Pubitemid 29245646)
43. Chilosi M, Doglioni C, Yan Z, et al. Differential expression of cyclin-dependent kinase 6 in cortical thymocytes and T-cell lymphoblastic lymphoma/leukemia. Am J Pathol. 1998;152(1):209-217. (Pubitemid 28028061)
44. Lien HC, Lin CW, Huang PH, Chang ML, Hsu SM. Expression of cyclin-dependent kinase 6 (cdk6) and frequent loss of CD44 in nasalnasopharyngeal NK/T-cell lymphomas: comparison with CD56-negative peripheral T-cell lymphomas. Lab Invest. 2000;80(6):893-900.
45. Schwartz R, Engel I, Fallahi-Sichani M, Petrie HT, Murre C. Gene expression patterns define novel roles for E47 in cell cycle progression, cytokinemediated signaling, and T lineage development. Proc Natl Acad Sci U S A. 2006;103(26):9976-9981. (Pubitemid 43993608)
46. Nagel S, Leich E, Quentmeier H, et al. Amplification at 7q22 targets cyclin-dependent kinase 6 in T-cell lymphoma. Leukemia. 2008;22(2):387-392. (Pubitemid 351250544)
47. Brito-Babapulle V, Gruszka-Westwood AM, Platt G, et al. Translocation t (2;7) (p12;q21-22) with dysregulation of the CDK6 gene mapping to 7q21-22 in a non-Hodgkin's lymphoma with leukemia. Haematologica. 2002;87(4):357-362. (Pubitemid 34297542)
48. Hayette S, Tigaud I, Callet-Bauchu E, et al. In B-cell chronic lymphocytic leukemias, 7q21 translocations lead to overexpression of the CDK6 gene. Blood. 2003;102(4):1549-1550. (Pubitemid 36988071)
49. Chen D, Law ME, Theis JD, et al. Clinicopathologic features of CDK6 translocation-associated B-cell lymphoproliferative disorders. Am J Surg Pathol. 2009;33(5):720-729.
50. Agirre X, Vilas-Zornoza A, Jimenez-Velasco A, et al. Epigenetic silencing of the tumor suppressor microRNA Hsa-miR-124a regulates CDK6 expression and confers a poor prognosis in acute lymphoblastic leukemia. Cancer Res. 2009;69(10):4443-4453.